Neuren Pharmaceuticals Limited

ASX:NEU Stock Report

Market Cap: AU$2.6b

Neuren Pharmaceuticals Future Growth

Future criteria checks 3/6

Neuren Pharmaceuticals is forecast to grow earnings and revenue by 5.2% and 13.5% per annum respectively. EPS is expected to grow by 4.9% per annum. Return on equity is forecast to be 34.6% in 3 years.

Key information

5.2%

Earnings growth rate

4.9%

EPS growth rate

Pharmaceuticals earnings growth27.3%
Revenue growth rate13.5%
Future return on equity34.6%
Analyst coverage

Low

Last updated04 Mar 2024

Recent future growth updates

Recent updates

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05
Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02
Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18
Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02
Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31
Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03
This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31
Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03
We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06
Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19
Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Jan 04
Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Earnings and Revenue Growth Forecasts

ASX:NEU - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20263191891801655
12/31/2025174961271225
12/31/20241549376875
12/31/2023232157185185N/A
9/30/2023155106120120N/A
6/30/202378555454N/A
3/31/202347282929N/A
12/31/202215044N/A
9/30/20229-3-3-3N/A
6/30/20223-7-10-10N/A
3/31/20223-7-10-10N/A
12/31/20213-8-10-10N/A
9/30/20212-10-10-10N/A
6/30/20211-12-9-9N/A
3/31/20211-11-9-9N/A
12/31/20201-9-8-8N/A
9/30/20201-8-9-9N/A
6/30/20200-8-9-9N/A
3/31/20200-9-10-10N/A
12/31/20190-11-12-12N/A
9/30/20197-6-5-5N/A
6/30/201914-122N/A
3/31/201914144N/A
12/31/201814366N/A
9/30/20187300N/A
6/30/201813-6-6N/A
3/31/201813-6-6N/A
12/31/201713-6-6N/A
9/30/20172-2N/A-7N/A
6/30/20173-8N/A-8N/A
3/31/20173-10N/A-10N/A
12/31/20163-12N/A-12N/A
9/30/20162-14N/A-14N/A
6/30/20160-15N/A-17N/A
3/31/20161-14N/A-15N/A
12/31/20152-13N/A-13N/A
9/30/20152-11N/A-11N/A
6/30/20153-9N/A-8N/A
3/31/20153-9N/A-7N/A
12/31/20143-8N/A-6N/A
9/30/20143-10N/A-7N/A
6/30/20143-12N/A-7N/A
3/31/20144-11N/A-7N/A
12/31/20135-10N/A-7N/A
9/30/20135-9N/A-7N/A
6/30/20135-6N/A-5N/A
3/31/20135-5N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NEU's forecast earnings growth (5.2% per year) is above the savings rate (2.2%).

Earnings vs Market: NEU's earnings (5.2% per year) are forecast to grow slower than the Australian market (13% per year).

High Growth Earnings: NEU's earnings are forecast to grow, but not significantly.

Revenue vs Market: NEU's revenue (13.5% per year) is forecast to grow faster than the Australian market (4.8% per year).

High Growth Revenue: NEU's revenue (13.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NEU's Return on Equity is forecast to be high in 3 years time (34.6%)


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.